Metastatic NSCLC; Phase I/II Other P001 Phase I 24 m December KEYNOTE001 Part A Study of 1246 2016 Cohort A Single Agent pts included 30 MK-3475 in patients with Patients 1191 different solid with pts tumour types Progressive (for for dose Locally all ranging. A total Advanced or P001) of 30 patients Metastatic received Carcinoma, pembrolizumab Melanoma, in this cohort. and Non- Small Cell Lung Carcinoma; Phase I P012 A Phase Ib May 2015 KEYNOTE012 is 114 al a II study of open pts follow pembrolizumab Study of label up in patients with in study 160 trial triple negative Subjects pts 12 breast cancer, with weeks head and neck Advanced until cancer, Solid death urothelial Tumours; or end cancer, or Phase I of gastric cancer. A study total of 225 patients have been treated with pembrolizumab. P013 A Ib 12 KEYNOTE013 is 106 weeks 2016 a phase II study pts; in patients with Study of hematologic in 36 malignancies. A Subjects pts total of 69 with patients have Hematologic been enrolled in this trial. Phase I P016 Phase 2 3 m Study of 71 2017 in pts; Patients with
Metastatic NSCLC; Phase I/II Other P001 Part A Phase I Study of Single Agent MK-3475 in Patients with Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non- Small Cell Lung Carcinoma; Phase I 1246 pts 1191 pts (for all P001) 24 m December 2016 KEYNOTE001 Cohort A included 30 patients with different solid tumour types for dose ranging. A total of 30 patients received pembrolizumab in this cohort. P012 A Phase Ib Study of in Subjects with Advanced Solid Tumours; Phase I open label study 114 pts 160 pts follow up 12 weeks until death or end of study May 2015 KEYNOTE012 is a II study of pembrolizumab in patients with triple negative breast cancer, head and neck cancer, urothelial cancer, or gastric cancer. A total of 225 patients have been treated with pembrolizumab. P013 A Ib Study of in Subjects with Hematologic Phase I 106 pts; 36 pts 12 weeks 2016 KEYNOTE013 is a phase II study in patients with hematologic malignancies. A total of 69 patients have been enrolled in this trial. P016 Phase 2 Study of in Patients with 71 pts; 3 m 2017 al trial
auspar-pembrolizumab-rch-161014.docx